Sodium Para-Aminobenzoate (“PABA”) in the Treatment of Dermatoses1  by Steiner, Karl & Grayson, Leonard D.
SODIUM PARA-AMINOBENZOATE ("PABA") IN THE TREATMENT
OF DERMATOSES5
LEONARD D. GRAYSON, M.D. AND KARL STEINER, M.D.t
Weiner (1) and Loewenthal (2) have recently reported good therapeutic
results when sodium para-aminobenzoate ("PABA") was given orally in daily
doses of 6 to 16 Gms. to patients with atopic dermatitis and other dermatitides.
Weiner noted an excellent and lasting response in S of 16 cases of atopic dermatitis
Four other patients showed an initial improvement but had a subsequent relapse.
In the other four patients the effect of PABA was unsatisfactory. Loewenthal
reported similar results in 18 cases of atopic dermatitis. Thirtyseven additional
cases of various forms of eczema showed an even more satisfactory response than
the atopic patients.
Loewenthal's rationale for the use of PABA in dermatitis was based on the
chemical relationship of the drug to the sulfonamides. He had previously ob-
served good results with sulfapyridine not only in dermatitis herpetiformis, as
is generally known, but in a variety of inflammatory skin diseases (3). This led
to his investigation of the effects of the "competitive analogue" to the sulfona-
mides, namely PABA, in these same diseases. Weiner referred to the findings of
Zarafonetis et al. (4) who noted a marked reduction of the inflammatory infil-
trate in collagen diseases. Zarafonetis reported also on good results with PABA
in dermatitis herpetiformis (5).
The European literature of the past 5—10 years contains many reports on
PABA. This drug has been used extensively in Italy, France, Germany and
Switzerland for the treatment of various dermatoses. Chiale (6), besides giving
an apparently complete bibliography of European papers, reports on the treat-
ment of 30 patients: 9 cases of psoriasis, 1 case of scleroderma, and 20 cases of
urticaria, eczema and "toxic-allergic" dermatitis. He reported diminution of
erythema, cessation of scaling and Koebner's phenomenon in psoriasis, and
similarly small improvement in all other diseases studied. Ferrucci (7) empha-
sized the antipruritic effect of intracutaneous doses of PABA when given every
1 to 3 days; otherwise, his results in eczema with doses similar to those used by
Chiale (5) were variable, the chronic cases in general show-ing a better response
than the acute cases.
EXPERIMENTAL
Stimulated by Weiner's and Loewenthal's results (1, 2) we administered
sodium para-aminobenzoate to 20 patients with various inflammatory skin
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diseases. The usual daily dose was 16 Gms., given in tablets of 0.5 Gms. each,
four times daily, after meals. Occasionally the dose had to be reduced because of
gastric upsets; in one case a mixture of 1 part of the potassium salt of PABA to
3 parts of the sodium salt was given because of dependent edema which developed
because of the high sodium intake. Apart from these complaints, and a rather
frequent but minimal "glycosuria", i.e. presence of a reducing substance in the
urine (see Grekin and Zarafonetis (8) ), no side-reactions were encountered,
even with large doses over periods of 3 months or more. However, it must be
mentioned that serious side-effects, e.g. toxic hepatitis and granulocytopenia,
have been seen by several authors from PABA (4).
The results are presented in Table 1. Two patients out of a total of 20 showed
good and lasting improvements; 4 had transient improvements, in 5 there were




DIAGNOSIS NUMBER OF _____________ __________ __________ __________CASES good and good but question- negativelasting transient able
Atopic dermatitis 8 1 1 4 2
Contact dermatitis and other
types of dermatitis 6 1 2 1 2
1)erm. herpetiform 1 — 1 — —
Psoriasis 1 — — — 1
Lichen planus 1 — — — 1
L. erythematosus, chron. discoid.. 1 — — — 1
Lichenoid and discoid dermatosis. 1 — — — 1
Dermatophytosis pedis with
phytid 1 1
Total 20 2 4 5 9
observed more frequently in patients with atopic and contact type dermatitis.
The improvement consisted in paling of inflammatory redness, diminution or dis-
appearance of edema, and considerable reduction of pruritus after an initial
period of a few days. The effects seemed unquestionably better and more clearly
pronounced in the acute cases. Increased pruritus occurred in most cases about
one week after start of the treatment with PABA. This pruritus impressed us as
a clinical effect of the treatment.
In an attempt at an objective evaluation of PABA on the skin, intracutaneous
tests with known allergenic substances were performed before the administration
of PABA, and repeated in several patients while under treatment with PABA*.
Neither these reactions nor spontaneous exacerbations in a case of atopic hyper-
sensitivity to chocolate could be prevented or suppressed by PABA.
* We are indebted to Dr. B. B. Siegel, Attending in Allergy, for the performance and in-
terpretation of these tests.
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Because of the clinical similarity of the effects of PABA to those of cortisone
and ACTH, Thorne tests were performed in 8 patients before and during the
treatment. In 4 of these patients the tests were done on 3 different occasions, in
3 on two occasions, and in one at the beginning of the treatment. A fasting eosino-
phil count was done at 8:30 a. m., and immediately thereafter 2—4 Gms. of PABA
were given. At 9:30 a. m. a second count was performed, and at 11:30 a. m. a
third count (in some cases at 12:30 p. m.). Surprisingly, in half of the tested pa-
tients positive results were obtained, i. e. decrease iii the number of circulating
eosinophils to less than 50 per cent, 1—3 hours after PABA. However, the results
showed no relation to the clinical response, and they were generally inconsistent.
On the other hand, a control test with physiological saline solution in the patient
with the most pronounced PABA response (from 325 eosinophils in 3 hours to 93
eosinophiles, i. e. a drop of 72 per cent) was negative; this seems to speak against
the eosinophilic response being a sodium effect. In another case the result of the
test with PABA was about the same as with ACTH and adrenalin (a drop of 47
per cent after 3 hours, the same with PABA as with ACTH).
COMMENTS
Since the patients treated with PABA suffered, in the main, from self-limited
diseases (allergic contact-type dermatitis) or certain types of dermatoses which
improve spontaneously on hospitalization (atopic dermatitis) and show irregular
remissions (dermatitis herpetiformis) all the observed results could certainly not
be attributed to the PABA treatment. Because of this questionable clinical effect
we discontinued the use of PABA after 20 patients had been treated. We are
therefore unable to confirm the good results obtained by Weiner, Loewenthal
and the European investigators (1, 2, 6, 7). However, we wish to emphasize three
points which might permit a different evaluation of the role of PABA in derma-
toses. First, because of the apparently good response in a few patients it might he
advisable to give PABA a trial in otherwise therapy-resistant cases, especially
those of acute character. Second, different modes of administration and dosage
might be tried, particularly parenteral administration as practiced be European
investigators. This would at least avoid the frequently bothersome gastric upsets
which accompany high oral doses. Third, the "stress" effect of PABA, as demon-
strated by the Thorne test, not only indicated that PABA has a definite action
but this response suggests perhaps another approach to the investigation of the
use of PABA and related substances.
SUMMARY
Twenty patients with a variety of inflammatory skin diseases received up to
16 Gms. of sodium para-aminobenzoate (PABA) daily by mouth for periods ranging
from 2 weeks to several months. Two of the 20 patients showed good and lasting
improvement. Four other cases responded initially but relapsed after a few weeks.
Intracutaneous reactions to known allergens were not changed by PABA.
There were positive Thorne test responses subsequent to the intake of 2 to 4
Gms. of PABA. These positive Thorne tests, though unrelated to clinical re-
sponses, indicated a definite effect of PABA.
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PABA might be tried in otherwise therapy-resistant inflammatory skin dis-
eases, and its effect by the parenteral route and in lower doses could be in-
vestigated.
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